A biological model of nervous system diseases based on Scn1a gene point mutations, its construction method and its application
By introducing the c.3750delC mutation into the mouse Scn1a gene through CRISPR/Cas9 gene editing, a mouse model carrying the Scn1a c.3750delC mutation was constructed. This addresses the shortcomings of existing models in simulating the consistency of chronic epilepsy with human diseases, providing an ideal research tool and enabling efficient research on epilepsy and neurological diseases.
Patent Information
- Application Number
- CN202510975159.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-15
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2045-07-15
AI Technical Summary
Existing mouse models of epilepsy are insufficient in simulating the pathological characteristics of chronic epilepsy, reflecting the epilepsy process, and are consistent with human disease. Furthermore, gene-edited models differ greatly from human physiology, affecting the accuracy and breadth of research results.
A mouse model carrying the Sn1a c.3750delC mutation was constructed by introducing the c.3750delC mutation into exon 20 of the mouse Sn1a gene using CRISPR/Cas9 gene editing technology, to simulate neurological diseases caused by loss of function of human Sn1A, especially Dravet syndrome.
It provides a mouse model with high genetic diversity and good experimental stability, enabling in-depth research on the role of SCN1A mutations in epilepsy and other neurological diseases, providing a key tool for gene therapy and drug development. Moreover, the mutation model is highly consistent with human diseases, making it suitable for mechanism research.
Smart Images

Figure CN121040426B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of transgenic technology, specifically involving the construction of a mouse model carrying the Scn1a c.3750delC mutation, which provides an ideal tool for in-depth research on the role of SCN1A mutations in epilepsy and other neurological diseases. Background Technology
[0002] Mouse models of epileptic seizures are important tools for studying the mechanisms of epilepsy and screening drugs. Existing models are mainly constructed through chemical induction, electroinduction, genetic modification, or pathological simulation. The following are common models and their main drawbacks:
[0003] I. Chemically induced models, such as (1) Pentetrazol (PTZ) model, which induces acute or chronic epileptic seizures through the GABA_A receptor antagonist PTZ. Disadvantages: This acute model is difficult to simulate the pathological features of chronic epilepsy (such as neuronal remodeling); seizure behavior varies greatly, making standardization difficult; it may cause widespread brain damage, which is quite different from human spontaneous epilepsy. (2) Pilocarpine model, which induces temporal lobe epilepsy (TLE) with hippocampal sclerosis using cholinergic agonists. Disadvantages: This model has a high mortality rate in the acute phase (requires the combination of anticholinergic drugs such as scopolamine); the latency period in the chronic phase is long (several weeks to several months), which is time-consuming; widespread damage to hippocampal neurons may interfere with mechanism research. (3) Kalinic acid (KA) model, which induces temporal lobe epilepsy using excitatory glutamate receptor agonists. Disadvantages: This model has high dose sensitivity, which can easily lead to uncontrollable severe seizures or death; the neuroinflammatory response is significant, which may confuse the specific mechanism of epilepsy.
[0004] II. Electrically induced models, such as (1) the maximal electroshock (MES) model, which induces tonic-clonic seizures through corneal or ear electrodes. Disadvantages: It only simulates acute seizures and is not suitable for chronic epilepsy research; it cannot reflect the epipileptogenesis process. (2) The amygdala / hippocampal kindling model, which uses repeated subthreshold electrical stimulation to induce progressive epilepsy susceptibility. Disadvantages: The modeling period is long (weeks to months); electrode implantation surgery may cause inflammation or mechanical damage that interferes with the results.
[0005] III. Hereditary epilepsy models, such as (1) spontaneously mutated mice (e.g., stargazer, tottering), utilizing naturally mutated epilepsy susceptibility genes (e.g., Cacna1a, Scn1a). Disadvantages: The phenotype may be limited to specific seizure types (e.g., absence seizures); background gene interference (e.g., ataxia) may affect behavioral analysis. (2) Gene editing models (e.g., SCN1A, KCNQ2 mutations), using CRISPR / Cas9 and other technologies to simulate human epilepsy-related gene mutations. Disadvantages: First, mice and humans have physiological and developmental differences, so mouse models may not be able to fully reproduce the complex symptoms of human diseases. Second, the specific genetic background of mice may lead to different disease manifestations, which affects the consistency and applicability of research results.
[0006] IV. Other models, such as (1) post-traumatic epilepsy model (TBI-induced), disadvantages: long and unpredictable seizure latency, low modeling success rate. (2) febrile seizure model, disadvantages: only applicable to developmental studies, limited correlation with adult epilepsy.
[0007] The SCN1A gene encodes the voltage-gated sodium channel Nav1.1, which is highly expressed in GABAergic inhibitory neurons and is responsible for regulating neuronal excitability homeostasis. Mutations in SCN1A are closely associated with various epilepsy syndromes, especially Dravet syndrome (DS). This invention utilizes CRISPR / Cas9 gene editing technology to prepare transgenic mice with the Scn1a c.3750delC (p.Thr1250fs*37) mutation, with a genetic background of 129S2 / SvPasCrl and C57 hybridization. This invention constructs an animal model simulating neurological diseases associated with the human Scn1ac.3750delC mutation, laying the foundation for elucidating the mechanisms of neurological dysfunction and exploring potential therapeutic strategies. Summary of the Invention
[0008] To address the problems existing in the prior art, the purpose of this invention is to design and provide a mouse model of spontaneous epilepsy caused by Scn1a point mutations, prepared using the CRISPR / Cas9 system, for mechanistic and therapeutic studies. The invention successfully constructed a mouse model carrying the Scn1a c.3750delC mutation through a hybridization background of 129S2 / SvPasCrl and C57BL / 6, exhibiting good genetic diversity and experimental stability. This provides an ideal tool for in-depth research on the role of SCN1A mutations in epilepsy and other neurological diseases, and also provides a crucial experimental foundation for gene therapy and drug development.
[0009] To achieve the above objectives, the present invention adopts the following technical solution:
[0010] On the one hand, the present invention provides a biological model of nervous system diseases based on point mutations in the Scn1a gene. By using gene editing to introduce a single base deletion mutation of c.3750delC into exon 20 of the Scn1a gene of an organism, an organism with symptoms of nervous system diseases is obtained.
[0011] The organisms referred to are mammals that do not include humans.
[0012] The aforementioned biological model of a nervous system disease based on point mutations in the Scn1a gene, wherein the nervous system disease is caused by loss-of-function mutations in SCN1A.
[0013] The aforementioned biological model of a nervous system disease based on point mutations in the Scn1a gene, wherein the nervous system disease is epilepsy.
[0014] The aforementioned biological model of a neurological disease based on a point mutation in the Scn1a gene, wherein the neurological disease is severe myoclonic epilepsy in infants.
[0015] The aforementioned biological model of a nervous system disease based on point mutations in the Scn1a gene, wherein the organism is a rodent.
[0016] The aforementioned biological model of a nervous system disease based on point mutations in the Scn1a gene, wherein the gene editing was performed using the CRISPR / Cas9 system.
[0017] Secondly, the present invention provides a method for constructing a biological model of a nervous system disease based on a point mutation in the Scn1a gene, as described in any one of the claims, comprising the following steps:
[0018] (1) Design and screen sgRNAs with low off-target effects and high cleavage efficiency targeting exon 20 of the Scn1a gene;
[0019] (2) Inject PMSG and HCG into female organisms and collect oocytes; at the same time, collect sperm from male organisms;
[0020] (3) Fertilized eggs are obtained by in vitro fertilization, and the sgRNA and Cas9 mRNA obtained in step (1) above are microinjected into the fertilized eggs;
[0021] (4) Perform embryo transfer, genotyping, and obtain an organism with the Scn1a c.3750delC gene mutation.
[0022] The nucleic acid sequence of the sgRNA in step (1) of the construction method described above is shown in SEQ ID NO.1.
[0023] Compared with the prior art, the present invention has the following beneficial effects:
[0024] This invention utilizes the CRISPR / Cas9 gene editing system to introduce a single-base deletion mutation, c.3750delC, into exon 20 of the mouse Scn1a gene. This mutation causes a frameshift in the protein coding process, generating a truncated Nav1.1 sodium ion channel, with the mutation form p.Thr1250fs*37. This type of mutation causes loss of function of the Nav1.1 channel, mimicking the loss-of-function mutation of SCN1A commonly found in patients with Dravet syndrome in humans. This mutation is located in the fourth homeo domain (DIV) of the SCN1A protein, which is responsible for regulating the inactivation mechanism of sodium channels. The mutation causes this mechanism to fail, preventing the normal closure of the sodium channel. The continuous influx of sodium ions leads to neuronal hyperexcitability, weakening the function of inhibitory γ-aminobutyric acid (GABAergic) neurons, and thus triggering epileptic seizures. This is highly consistent with the seizure mechanism of severe myoclonic epilepsy in infants (Dravet syndrome). Attached Figure Description
[0025] Figure 1 Genotyping results for Scn1a c.3750delC(p.Thr1250fs*37) mice;
[0026] Figure 2 Phenotypic identification results for Scn1a c.3750delC(p.Thr1250fs*37) mice. Detailed Implementation
[0027] The present invention will be further described below with reference to the accompanying drawings and embodiments.
[0028] Example 1:
[0029] By precisely editing the Scn1a gene using CRISPR / Cas9 technology and combining it with 129S2 / SvPasCrl and C57BL / 6 hybrid background mice, a mouse model carrying the c.3750delC mutation was successfully constructed. The specific steps are as follows:
[0030] 1. sgRNA design and cleavage efficiency detection:
[0031] 1) Use online tools to design sgRNAs for Scn1a Exon20, selecting sequences with low off-target effects.
[0032] 2) The cleavage efficiency was detected by in vitro cleavage assay (T7EI or Surveyor Assay), and the most efficient sgRNA (SEQ ID NO.1, AAAGACGATCAAAACCATGC) was selected for subsequent experiments.
[0033] 2. Superovulation and sperm collection:
[0034] Superovulation was induced by intraperitoneal injection of 5 IU of pregnant mare serum gonadotropin (PMSG) into each 4-week-old female mouse using a sterile syringe. 46-48 hours later, 5 IU of human chorionic gonadotropin (HCG) was injected intraperitoneally into each mouse. Oocytes were then collected within 13-16 hours and released from the ampulla of the fallopian tube into the fertilization fluid under a stereomicroscope for fertilization.
[0035] Sperm collection was performed on adult male C57BL / 6 mice aged 8-10 weeks. After euthanasia by dislocation, the epididymis was removed, cut open, and sperm released into a sperm activation solution. The sperm was activated for one hour, and then 2 μL of activated sperm was aspirated and added to the oocyte fertilization solution for in vitro fertilization to obtain zygotes. SpCas9-mRNA and gRNA were injected into the pronucleus of the zygotes via microinjection and then transplanted into the ampulla of the oviduct of a CD1 surrogate mother mouse. The surrogate mouse was weighed every week to preliminarily determine pregnancy. Pups were born 19-21 days post-surgery. Five days after birth, the pups were tail-cropped, numbered, and subjected to PCR testing.
[0036] 3. Identification of F0 / F1 mice
[0037] Based on the sgRNA site of the Scn1a gene, a pair of primers F1 / R1 were designed at both ends of the mutation site. We performed PCR primer amplification on newborn F0 mice and sent them for sequencing. The product amplified by the primers in gene knockout mice was 698 bp. Sanger sequencing was used, and the mice were identified using sequencing primer F2. Figure 1 Scn1a mice with successful mutations were used as fathers / mothers for breeding. Correctly identified positive mice were mated with wild-type mice in the same cage to obtain F1 mice. Fourteen days after birth, mice were identified as homozygous by PCR amplification using the same primers as above. Sanger sequencing was used for identification. F1 (SEQ ID NO.2): GGGAACTGGGAAAGGGGATAACATT
[0038] R1(SEQ ID NO.3):CAACACAGTGGCCCGAGACTCATTC
[0039] F2(SEQ ID NO.4):AGGAAATACCATGTGCATAT
[0040] The final Scn1a c.3750delC (p.Thr1250fs*37) mouse was obtained, in which a C deletion occurred at the 3750th base of the Scn1a gene, resulting in a frameshift mutation in the protein coding process. This caused the original threonine (Thr) at position 1250 to be replaced, followed by a termination signal at position 37, forming a truncated protein and leading to the loss of function of the Nav1.1 protein encoded by this gene. The SCN1A mutation affects sodium channel function in GABAergic inhibitory neurons, leading to reduced activity of inhibitory neurons. This neuronal dysregulation often results in hyperexcitability of the brain, especially when exposed to heat or fever. In mouse models carrying the SCN1A mutation, exposure to high temperatures can induce seizures, similar to the symptoms of human heat-sensitive epilepsy. This response is one of the typical phenotypes of Dravet syndrome and related SCN1A mutations.
[0041] Therefore, we conducted an experiment to induce epilepsy by heat, and the results were as follows: Figure 2 This demonstrated the epileptic phenotype of the transgenic animal.
Claims
1. A method for constructing a biological model of nervous system diseases based on point mutations in the Scn1a gene, characterized in that, Includes the following steps: (1) Design and screen sgRNAs with low off-target effects and high cleavage efficiency targeting exon 20 of the Scn1a gene; (2) Inject PMSG and HCG into female organisms and collect oocytes; at the same time, collect sperm from male organisms; (3) Fertilized eggs are obtained by in vitro fertilization, and the sgRNA and Cas9 mRNA obtained in step (1) above are microinjected into the fertilized eggs; (4) Perform embryo transfer, genotyping, and obtain an organism with the Scn1a c.3750delC gene mutation; The organism in question is a mouse.
2. The construction method as described in claim 1, characterized in that, The nucleic acid sequence of the sgRNA mentioned in step (1) is shown in SEQ ID NO.
1.
3. The construction method as described in claim 1, characterized in that, The neurological disease mentioned is caused by a loss-of-function mutation in SCN1A.
4. The construction method as described in claim 3, characterized in that, The neurological disorder is epilepsy.
5. The construction method as described in claim 4, characterized in that, The neurological disorder is severe myoclonic epilepsy in infants.
Citation Information
Patent Citations
Treatment / prevention of diseases by inhibition of LINC complexes
CN114585392A
Construction and application of model of sudden epilepsy death animal caused by Kcna1 gene knockout
CN118956953A
